2期临床-话题@MedSci

#2期临床#

38篇内容 | 1580人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1970258, encodeId=335519e025881, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=AAN：Magenta Therapeutics的干细胞疗法MGTA-456的2期临床数据喜人, objectType=article, longId=165895, objectId=49e916589568, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49e916589568, replyNumber=0, likeNumber=65, createdTime=2020-03-21, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49e916589568, moduleTitle=AAN：Magenta Therapeutics的干细胞疗法MGTA-456的2期临床数据喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49e916589568)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970259, encodeId=c2ca19e025930, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=Brit J Cancer：舒尼替尼治疗进展性副神经节瘤或嗜铬细胞瘤的2期临床试验, objectType=article, longId=166542, objectId=1d3516654213, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d3516654213, replyNumber=0, likeNumber=72, createdTime=2020-02-09, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d3516654213, moduleTitle=Brit J Cancer：舒尼替尼治疗进展性副神经节瘤或嗜铬细胞瘤的2期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d3516654213)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970260, encodeId=690319e02605a, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=2019 ASCO：诺华和默克治疗MET突变非小细胞肺癌的候选药，在2期临床均显示出治疗活性, objectType=article, longId=167679, objectId=019216e679c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=019216e679c8, replyNumber=0, likeNumber=68, createdTime=2019-08-19, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=019216e679c8, moduleTitle=2019 ASCO：诺华和默克治疗MET突变非小细胞肺癌的候选药，在2期临床均显示出治疗活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=019216e679c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970255, encodeId=ea7b19e025514, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=礼来JAK抑制剂Olumiant治疗系统性红斑狼疮的2期临床试验获得成功, objectType=article, longId=145138, objectId=96a9145138b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96a9145138b2, replyNumber=0, likeNumber=59, createdTime=2018-12-08, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96a9145138b2, moduleTitle=礼来JAK抑制剂Olumiant治疗系统性红斑狼疮的2期临床试验获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96a9145138b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970257, encodeId=3b5a19e0257d2, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=治疗艾滋病，ViiV Healthcare公司的长效注射药物2期临床数据振奋人心, objectType=article, longId=152466, objectId=84471524662d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84471524662d, replyNumber=0, likeNumber=120, createdTime=2019-05-26, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84471524662d, moduleTitle=治疗艾滋病，ViiV Healthcare公司的长效注射药物2期临床数据振奋人心, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84471524662d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970254, encodeId=578c19e02540c, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=J Am Acad Dermatol：NK1R拮抗剂治疗慢性瘙痒的2期临床试验, objectType=article, longId=131180, objectId=aaf31311809d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aaf31311809d, replyNumber=0, likeNumber=64, createdTime=2018-11-26, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aaf31311809d, moduleTitle=J Am Acad Dermatol：NK1R拮抗剂治疗慢性瘙痒的2期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aaf31311809d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970256, encodeId=b06d19e0256c3, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=希望！阿尔茨海默病新药2期临床全新出炉，减缓认知衰退效果显著, objectType=article, longId=145569, objectId=885514556997, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=885514556997, replyNumber=0, likeNumber=102, createdTime=2019-01-15, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=885514556997, moduleTitle=希望！阿尔茨海默病新药2期临床全新出炉，减缓认知衰退效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=885514556997)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970251, encodeId=ea4b19e0251d4, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=慢性肾病相关贫血新药vadadustat展现出色2期临床数据, objectType=article, longId=114459, objectId=9e491144599a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e491144599a, replyNumber=0, likeNumber=85, createdTime=2017-12-29, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e491144599a, moduleTitle=慢性肾病相关贫血新药vadadustat展现出色2期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e491144599a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970253, encodeId=c50219e0253e9, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=Blood：brentuximab vedotin治疗复发或难治性系统性间变性大细胞淋巴瘤的2期临床报告, objectType=article, longId=115405, objectId=751111540543, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=751111540543, replyNumber=0, likeNumber=46, createdTime=2018-06-06, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=751111540543, moduleTitle=Blood：brentuximab vedotin治疗复发或难治性系统性间变性大细胞淋巴瘤的2期临床报告, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=751111540543)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970250, encodeId=4f1819e02502b, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=J Gastroenterol：乐伐替尼晚期肝细胞癌2期临床研究, objectType=article, longId=93557, objectId=40529355e79, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40529355e79, replyNumber=0, likeNumber=76, createdTime=2017-07-05, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40529355e79, moduleTitle=J Gastroenterol：乐伐替尼晚期肝细胞癌2期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40529355e79)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970248, encodeId=3dd719e024831, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=治疗2型糖尿病 Ionis新药2期临床良好, objectType=article, longId=86910, objectId=92008691089, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92008691089, replyNumber=0, likeNumber=62, createdTime=2017-11-30, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92008691089, moduleTitle=治疗2型糖尿病 Ionis新药2期临床良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92008691089)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970252, encodeId=411c19e0252c1, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=起死回生！罕见病新药2期临床收获积极结果, objectType=article, longId=114833, objectId=cc8711483319, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc8711483319, replyNumber=0, likeNumber=69, createdTime=2018-03-16, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc8711483319, moduleTitle=起死回生！罕见病新药2期临床收获积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc8711483319)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970249, encodeId=bad419e0249af, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=isterra正式启动甲型流感药物VIS410的2期临床试验, objectType=article, longId=87622, objectId=8b868e622a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b868e622a4, replyNumber=0, likeNumber=53, createdTime=2017-05-20, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b868e622a4, moduleTitle=isterra正式启动甲型流感药物VIS410的2期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b868e622a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970247, encodeId=22dd19e024748, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=干细胞解冻“渐冻人”，2期临床顺利收官, objectType=article, longId=73388, objectId=954be3388f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=954be3388f5, replyNumber=0, likeNumber=65, createdTime=2017-01-09, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=954be3388f5, moduleTitle=干细胞解冻“渐冻人”，2期临床顺利收官, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=954be3388f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970246, encodeId=cc8f19e024607, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=NEJM：端粒酶抑制剂imetelstat用于骨髓纤维化和原发性血小板增多症疗效乐观（2期临床）, objectType=article, longId=55964, objectId=362d559648b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=362d559648b, replyNumber=0, likeNumber=73, createdTime=2016-01-18, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=362d559648b, moduleTitle=NEJM：端粒酶抑制剂imetelstat用于骨髓纤维化和原发性血小板增多症疗效乐观（2期临床）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=362d559648b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970243, encodeId=1d6019e024300, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=Lancet Neurol：2期临床研究显示idalopirdine可改善中度AD患者认知, objectType=article, longId=41535, objectId=60e44153595, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60e44153595, replyNumber=0, likeNumber=54, createdTime=2015-02-05, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60e44153595, moduleTitle=Lancet Neurol：2期临床研究显示idalopirdine可改善中度AD患者认知, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60e44153595)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970245, encodeId=771319e02457e, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=Int J Radiat Oncol Biol Phys：术前放化疗结合帕尼单抗治疗可切除食管癌：2期临床试验, objectType=article, longId=42694, objectId=ffe84269456, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffe84269456, replyNumber=0, likeNumber=62, createdTime=2015-05-16, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffe84269456, moduleTitle=Int J Radiat Oncol Biol Phys：术前放化疗结合帕尼单抗治疗可切除食管癌：2期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffe84269456)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1970244, encodeId=73fd19e024487, content=<a href='/topic/show?id=7cb11116d7' target=_blank style='color:#2F92EE;'>#2期临床#</a>, objectTitle=JAMA：A/H7N9型禽流感疫苗与MF59佐剂混合使用安全有效（2期临床试验）, objectType=article, longId=42029, objectId=af7b42029e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af7b42029e4, replyNumber=0, likeNumber=53, createdTime=2015-04-20, rootId=0, userName=ysjykql, userId=96d4340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af7b42029e4, moduleTitle=JAMA：A/H7N9型禽流感疫苗与MF59佐剂混合使用安全有效（2期临床试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af7b42029e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

2期临床

2020-05-29

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

AAN：Magenta Therapeutics的干细胞疗法MGTA-456的2期临床数据喜人

2020-03-21

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

Brit J Cancer：舒尼替尼治疗进展性副神经节瘤或嗜铬细胞瘤的2期临床试验

2020-02-09

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

2019 ASCO：诺华和默克治疗MET突变非小细胞肺癌的候选药，在2期临床均显示出治疗活性

2019-08-19

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

礼来JAK抑制剂Olumiant治疗系统性红斑狼疮的2期临床试验获得成功

2018-12-08

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

治疗艾滋病，ViiV Healthcare公司的长效注射药物2期临床数据振奋人心

2019-05-26

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

J Am Acad Dermatol：NK1R拮抗剂治疗慢性瘙痒的2期临床试验

2018-11-26

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

希望！阿尔茨海默病新药2期临床全新出炉，减缓认知衰退效果显著

2019-01-15

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

慢性肾病相关贫血新药vadadustat展现出色2期临床数据

2017-12-29

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

Blood：brentuximab vedotin治疗复发或难治性系统性间变性大细胞淋巴瘤的2期临床报告

2018-06-06

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

J Gastroenterol：乐伐替尼晚期肝细胞癌2期临床研究

2017-07-05

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

治疗2型糖尿病 Ionis新药2期临床良好

2017-11-30

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

起死回生！罕见病新药2期临床收获积极结果

2018-03-16

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

isterra正式启动甲型流感药物VIS410的2期临床试验

2017-05-20

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

干细胞解冻“渐冻人”，2期临床顺利收官

2017-01-09

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

NEJM：端粒酶抑制剂imetelstat用于骨髓纤维化和原发性血小板增多症疗效乐观（2期临床）

2016-01-18

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

Lancet Neurol：2期临床研究显示idalopirdine可改善中度AD患者认知

2015-02-05

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

Int J Radiat Oncol Biol Phys：术前放化疗结合帕尼单抗治疗可切除食管癌：2期临床试验

2015-05-16

ysjykql (审核中...)

前往app查看评论内容

#2期临床#

JAMA：A/H7N9型禽流感疫苗与MF59佐剂混合使用安全有效（2期临床试验）

2015-04-20

科室
- - 订阅+
  - 更多科室
工具
服务